论文部分内容阅读
本刊讯澳大利亚医疗产品管理局(TGA)在2015年第4期《药品安全性更新》中通告了修订利培酮说明书事宜,限制该品种在痴呆患者中的适应证及疗程。利培酮是一种非典型抗精神病药,属于苯异唑衍生物。它是一种选择性单胺能受体拮抗药,对血清素能5-HT2受体、多巴胺D2受体和α1肾上腺素受体有高度亲和力。药品生产企业Janssen-Cilag公司向TGA提交的一项临床对照研究结果发现,与接受利培酮治疗的阿尔茨海默病痴呆
The Journal of the Australian Medical Products Agency (TGA) announced the revision of the Risperidone specification in the 4th issue of the Drug Safety Update in 2015 to limit the indications and course of treatment of this variety in patients with dementia. Risperidone is an atypical antipsychotic and belongs to the benzoxazole derivatives. It is a selective antagonist of monoaminergic receptors with a high affinity for serotonergic 5-HT2 receptors, dopamine D2 receptors and α1 adrenoceptors. A clinical controlled study by drug manufacturer Janssen-Cilag submitted to the TGA found that patients with Alzheimer’s dementia who were treated with risperidone